File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00213-014-3722-z
- Scopus: eid_2-s2.0-84922830786
- PMID: 25155312
- WOS: WOS:000349377000007
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users
Title | A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users |
---|---|
Authors | |
Keywords | Amphetamines Drug abuse Ecstasy MDMA Neurotoxicity Psychopathology |
Issue Date | 2015 |
Citation | Psychopharmacology, 2015, v. 232, n. 5, p. 897-905 How to Cite? |
Abstract | Aims: It still remains unclear whether psychopathological abnormalities described in human 3,4-methylenedioxymethamphetamine users (MDMA users) and d-amphetamine users (AMPH users) existed before the beginning of regular use or if they develop with ongoing use. Objectives: The present study was conducted in order to assess this relationship and to overcome previous methodological shortcomings. Methods: A longitudinal cohort study in 96 beginning MDMA and d-amphetamine users between 2006 and 2011 with a follow-up duration of 24 months. In order to explore the impact of MDMA and AMPH use on self-reported psychopathology (measured by the Symptom Checklist-90-Revised), mixed models for repeated measures were fitted. In order to examine the impact of previous psychopathology on subsequent use, partial correlation analyses and linear regression analyses were applied. Results: Over the course of the 2-year follow-up period, 31 subjects used neither MDMA nor AMPH (non-users); 65 subjects used both MDMA and AMPH: 37 subjects used between 1 and 14 tablets of MDMA and 28 subjects used 15 or more tablets of MDMA. Thirty-three subjects used between 1 and 14 g of AMPH, and 32 subjects used 15 g or more. No associations concerning MDMA/AMPH use and development of self-reported psychopathology were found. However, there was a significant relationship between globally increased self-reported psychopathology - particularly psychoticism - at the beginning of the study and subsequent AMPH use. Conclusions: The data of the present study suggest that a certain psychopathological profile could form a risk factor for later use of amphetamines. |
Persistent Identifier | http://hdl.handle.net/10722/330373 |
ISSN | 2021 Impact Factor: 4.415 2020 SCImago Journal Rankings: 1.378 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wagner, Daniel | - |
dc.contributor.author | Koester, Philip | - |
dc.contributor.author | Becker, Benjamin | - |
dc.contributor.author | Gouzoulis-Mayfrank, Euphrosyne | - |
dc.contributor.author | Hellmich, Martin | - |
dc.contributor.author | Daumann, Joerg | - |
dc.date.accessioned | 2023-09-05T12:10:01Z | - |
dc.date.available | 2023-09-05T12:10:01Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Psychopharmacology, 2015, v. 232, n. 5, p. 897-905 | - |
dc.identifier.issn | 0033-3158 | - |
dc.identifier.uri | http://hdl.handle.net/10722/330373 | - |
dc.description.abstract | Aims: It still remains unclear whether psychopathological abnormalities described in human 3,4-methylenedioxymethamphetamine users (MDMA users) and d-amphetamine users (AMPH users) existed before the beginning of regular use or if they develop with ongoing use. Objectives: The present study was conducted in order to assess this relationship and to overcome previous methodological shortcomings. Methods: A longitudinal cohort study in 96 beginning MDMA and d-amphetamine users between 2006 and 2011 with a follow-up duration of 24 months. In order to explore the impact of MDMA and AMPH use on self-reported psychopathology (measured by the Symptom Checklist-90-Revised), mixed models for repeated measures were fitted. In order to examine the impact of previous psychopathology on subsequent use, partial correlation analyses and linear regression analyses were applied. Results: Over the course of the 2-year follow-up period, 31 subjects used neither MDMA nor AMPH (non-users); 65 subjects used both MDMA and AMPH: 37 subjects used between 1 and 14 tablets of MDMA and 28 subjects used 15 or more tablets of MDMA. Thirty-three subjects used between 1 and 14 g of AMPH, and 32 subjects used 15 g or more. No associations concerning MDMA/AMPH use and development of self-reported psychopathology were found. However, there was a significant relationship between globally increased self-reported psychopathology - particularly psychoticism - at the beginning of the study and subsequent AMPH use. Conclusions: The data of the present study suggest that a certain psychopathological profile could form a risk factor for later use of amphetamines. | - |
dc.language | eng | - |
dc.relation.ispartof | Psychopharmacology | - |
dc.subject | Amphetamines | - |
dc.subject | Drug abuse | - |
dc.subject | Ecstasy | - |
dc.subject | MDMA | - |
dc.subject | Neurotoxicity | - |
dc.subject | Psychopathology | - |
dc.title | A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s00213-014-3722-z | - |
dc.identifier.pmid | 25155312 | - |
dc.identifier.scopus | eid_2-s2.0-84922830786 | - |
dc.identifier.volume | 232 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 897 | - |
dc.identifier.epage | 905 | - |
dc.identifier.eissn | 1432-2072 | - |
dc.identifier.isi | WOS:000349377000007 | - |